DGAP-News

aap Implantate AG: Successful start in 2017 with sales and EBITDA increase - 30% sales growth in trauma in Q1/2017 - Seite 2

- LOQTEQ(R): Completion of portfolio with a focus on the preparation of approvals for further polyaxial LOQTEQ(R) systems


- Silver coating technology: Focus on coordinating scope of clinical study with notified body and US FDA; approach, timetable and required resources will be published in a separate release

Q1/2017 - Financials

Sales

In EUR million	Q1/2017	Q1/2016	Change on year
Trauma thereof North America and Europe thereof RoW	2.9 2.1 0.8	2.2 1.8 0.4	+30% +16% +87%
Other (mainly discontinued activities)	0.2	0.3	-34%
Sales	3.1	2.5	+23%

 

With regard to the sales development, it turns out that the dynamic development in North America and Europe continued in the first quarter of 2017. This reflects simultaneously the progress in the targeted distribution focus on established markets such as North America, the DACH region and further European countries. Besides this the sales development in BRICS and SMIT states shows a positive trend towards stabilization.

 

EBITDA

In EUR million	Q1/2017	Q1/2016	Change on year
EBITDA	-1.7	-2.2	+23%
One-time effects	0.5*	0.2**	>100%
Recurring EBITDA	-1.2	-2.0	+39%

*Includes costs for "Quality First" project, depreciation on raw materials and pre-operating costs set-up distribution business North America